Changes in fecal microbiota composition in patients with Huntington’s disease in China
Objective: Gut-brain axis has been associated with multiple brain disorders [1,2,3]. This study is to explore fecal microbiota changes in Huntington's disease (HD). Background: Huntington's…Huntington’s disease in Egypt; A big challenge for a mysterious disease
Objective: To identify the challenges of managing Huntington’s disease in Egypt in order to overcome them. Background: Huntington’s disease (HD) is considered a rare disease…Differential burden of comorbidities for Huntington’s Disease, Parkinson’s Disease and the general population for patients and care partners in the US
Objective: Describe the comorbidity burden for patients (pt) and care partners (cp) of Huntington’s Disease (HD), Parkinson’s Disease (PD) and the general population (GP) Background:…Epidemiology of Huntington’s Disease (HD) in the US Medicaid Population
Objective: To estimate the current prevalence of Huntington’s disease (HD) among Medicaid beneficiaries in the United States (US). Background: HD is a genetic, progressive, neurodegenerative…Healthcare resource utilisation and costs among patients with versus without Huntington’s disease in the US population
Objective: Compare the marginal healthcare resource utilisation (HRU) and costs between US patients with Huntington’s disease (HD) and non-HD controls. Background: HD is a genetic,…Deutetrabenazine for Huntington’s disease chorea—A Single Center’s Experience
Objective: To evaluate real-world use and outcomes with deutetrabenazine for Huntington’s disease. Background: Grade A evidence for Huntington’s disease chorea treatment includes tetrabenazine and deutetrabenazine.…Evaluation of the Safety of Deutetrabenazine at Higher Doses to Treat Chorea in Huntington’s Disease
Objective: To evaluate the safety and tolerability of deutetrabenazine >48 mg/d compared to ≤48 mg/d to treat Huntington’s disease (HD)–associated chorea in ARC-HD. Background: In…VMAT 2 inhibitor and Antipsychotic use in Individuals with Huntington’s Disease
Objective: To retrospectively investigate whether the concomitant use of VMAT2 inhibitors and antipsychotics in individuals with Huntington's disease (HD) is associated with an increased occurrence…Association between the number of CAG repetitions and cognitive performance in Huntington’s disease in patients of the National Institute of Neurology and Neurosurgery “MVS”
Objective: To establish the relationship between the number of CAG repetitions and the total Montreal Cognitive Assessment (MoCA) scores in patients with Huntington disease (HD).…Cardiovascular risk factors in a pre-manifest and manifest population of Huntington’s disease
Objective: To identify cardiovascular risk factors in a self-reported series of local Huntington's disease participants in the ENROLL-HD registry Background: Population studies have contributed to…
- « Previous Page
- 1
- …
- 777
- 778
- 779
- 780
- 781
- …
- 1554
- Next Page »